Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Risk factors

Topic: Brain proteins, microglia and lab models

Plain-language summary

APOE4 is the strongest genetic risk factor associated with late-onset Alzheimer's disease (AD). To address the underlying mechanism, we develop cerebral organoid models using induced pluripotent stem cells (iPSCs) with APOE ε3/ε3 or ε4/ε4 genotype from individuals with either normal cognition or AD dementia. Cerebral organoids from AD patients carrying APOE ε4/ε4 show greater apoptosis and decreased synaptic integrity. While AD patient-derived cerebral organoids have increased levels of Aβ and phosphorylated tau compared to healthy subject-derived cerebral organoids, APOE4 exacerbates tau pathology in both healthy subject-derived and AD patient-derived organoids. Transcriptomics analysis by RNA-sequencing reveals that cerebral organoids from AD patients are associated with an enhancement of stress granules and disrupted RNA metabolism. Importantly, isogenic conversion of APOE4 to APOE3 attenuates the APOE4-related phenotypes in cerebral organoids from AD patients. Together, our study using human iPSC-organoids recapitulates APOE4-related phenotypes and suggests APOE4-related degenerative pathways contributing to AD pathogenesis.

What this study adds

Evidence grade: Low

In lab-grown human brain organoids, the APOE4 gene variant worsened synapse loss, tau pathology and cell death compared with APOE3. Converting APOE4 to APOE3 reduced these effects, suggesting APOE4-related pathways as possible targets, but this is early laboratory work, not a treatment.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Zhao, J., Fu, Y., Yamazaki, Y., Ren, Y., Davis, M. D., Liu, C. C., et al. (2020). APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. Nature communications. https://doi.org/10.1038/s41467-020-19264-0

Vancouver

Zhao J, Fu Y, Yamazaki Y, Ren Y, Davis MD, Liu CC, et al. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. Nature communications. 2020. doi:10.1038/s41467-020-19264-0. PMID: 33139712.

BibTeX

@article{zhao2020-33139712,
  author  = {Zhao, J. and Fu, Y. and Yamazaki, Y. and Ren, Y. and Davis, M. D. and Liu, C. C. and Lu, W. and Wang, X. and others},
  title   = {{APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids}},
  journal = {Nature communications},
  year    = {2020},
  doi     = {10.1038/s41467-020-19264-0},
  pmid    = {33139712},
  url     = {https://doi.org/10.1038/s41467-020-19264-0}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In lab-grown human brain organoids, the APOE4 gene variant worsened synapse loss, tau pathology and cell death compared with APOE3. Converting APOE4 to APOE3 reduced these effects, suggesting APOE4-related pathways as possible targets, but this is early laboratory work, not a treatment.

Study details

How this study scored 58/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 2 of 6; Still being cited 4 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 58 of 100.58 of 100 points earned42 not earned

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Nature communications)
Journal's citation record 4 / 4 Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Laboratory or animal study (title names “ipsc”) — scores zero
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 375 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 46.9 citations a year over 8 year(s) since 2020
Impact for its field and year 5 / 6 Cited 22.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 8 other studies in this library
Still being cited 4 / 4 Cited 206 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Guojun Bu: h-index 120 (OpenAlex, whole career)
Institution's track record 2 / 3 Mayo Clinic: institution h-index 1,606 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 33139712)
Free to read 2 / 2 Free to read
Total 58 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

8 studies in the alzhub library list this one in their references.

Related studies in Risk factors from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk factors

See all studies in Risk factors →